Overview

The global AI Drug Discovery Market was valued at USD 2.5 billion in 2025 and is projected to reach USD 15.5 billion by 2034, growing at a CAGR of 22.3% during the forecast period (2026–2034). The market is driven by the need to shorten early discovery timelines, lower late-stage attrition, and make better use of large biological and chemical datasets. Pharmaceutical and biotechnology companies now buy AI-designed candidates, prediction software, and model access from specialist vendors and technology providers, and investors are backing AI-native developers through large private rounds and public listings. The market is shifting from conventional, stand-alone prediction tools toward integrated platforms that link AI models with automated laboratories, so every experiment improves the next design cycle. Generative models now create molecules and antibodies from scratch, foundation models predict how molecules bind to proteins, and AI agents help scientists analyze patient data.  Government initiatives such as the Guiding Principles of Good AI Practice in Drug Development, published jointly by the European Medicines Agency and the U.S. Food and Drug Administration in January 2026, give developers a common framework for using AI across the medicine lifecycle. The ten principles cover risk-based use, clear context of use, data governance, and life cycle management, which lowers regulatory uncertainty for sponsors that submit AI-generated evidence. The principles apply from early research through manufacturing and post-market monitoring, so AI vendors can align product design with one shared expectation. By region, North America held the largest share of the market in 2025, supported by its dense concentration of AI-native drug developers, technology providers, and large pharmaceutical sponsors in the United States. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by expanding AI drug discovery activity in China and Japan.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Foundation Models and Closed-Loop Laboratories Emerging as a Transformational Trend

• Drug discovery teams are moving from single-purpose prediction tools to foundation models trained on protein, chemical, and cell-imaging data. One model can now estimate structure, binding, and toxicity together, so chemists synthesize far fewer molecules before choosing a lead. This shift is changing how research budgets are split between software licences and laboratory work.
• AI models are increasingly being connected with experimental workflows to create iterative “lab-in-the-loop” systems. In this approach, computational models generate or prioritize hypotheses, automated or high-throughput experiments produce new data, and those results are fed back into the models for subsequent design cycles. This integration can reduce the separation between computational prediction and laboratory validation.
• The competitive focus is therefore shifting toward platforms that combine advanced models, proprietary biological data, computing infrastructure, and experimental capabilities. As foundation models become more general-purpose, access to high-quality experimental data and the ability to continuously validate model outputs are becoming important differentiators for AI drug-discovery providers.
• NVIDIA and Eli Lilly announced an AI co-innovation lab in the San Francisco Bay Area, backed by up to USD 1 billion of joint investment over five years in talent, infrastructure, and compute. The lab runs on the NVIDIA BioNeMo platform and targets closed-loop discovery, where AI models and laboratory experiments improve each other in continuous cycles.

KEY MARKET DRIVER

Rising Need to Shorten Discovery Timelines and Reduce Late-Stage Attrition is the Key Driver

• The growing cost and complexity of drug development is increasing demand for AI tools that can identify weak candidates earlier in the discovery process. AI-based target identification, molecular design, virtual screening, and property prediction can help researchers prioritize experiments and reduce resources spent on less promising candidates.
• Increasing availability of large-scale biological and chemical datasets is strengthening the effectiveness and adoption of AI-driven discovery platforms. Public initiatives such as the NIH's National Center for Advancing Translational Sciences (NCATS) and National Library of Medicine (NLM) provide researchers with extensive biomedical datasets and computational resources, supporting the development and validation of AI models for drug discovery.
• Regulatory efforts to establish standards for credible AI models are supporting wider use of AI in drug development. The FDA has introduced a risk-based framework for assessing the credibility of AI models used in regulatory decision-making, encouraging developers to demonstrate model reliability, performance, and applicability before AI-generated evidence is used to support drug-development decisions.
• The U.S. FDA published a roadmap to reduce animal testing in preclinical safety studies, starting with monoclonal antibodies. The plan encourages AI-based computational toxicity models and organ-on-a-chip data, and the agency reported first-year progress in April 2026, which raises demand for in silico safety tools across the industry.

KEY MARKET OPPORTUNITY

Federated and Platform-Based Access Models Opening Discovery Capabilities to Smaller Biotechs

• Most early-stage biotechs lack the large, high-quality datasets needed to train reliable models. Shared platforms that let many companies improve a model without exposing raw data are creating a new service category, and vendors that can host such networks will earn recurring revenue from access, model tuning, and independent validation across many small customers.
• Biologics design is an untapped area for smaller teams. Software that generates antibodies and proteins from scratch lets a start-up enter large-molecule programs that once needed big screening facilities, so vendors can sell design software, custom models, and laboratory validation as separate paid services. Smaller teams gain speed, while vendors gain a wider customer base than large pharmaceutical sponsors alone.
• Asia-Pacific pharmaceutical and biotechnology companies want AI partners to shorten local discovery timelines, while global sponsors want faster and lower-cost early-stage programs. This two-way demand opens room for cross-border licensing and co-development models that attract investors looking for milestone-linked returns. Regional partners also bring patient access, clinical trial capacity, and faster manufacturing routes that Western platform companies often lack.
• Eli Lilly launched Lilly TuneLab, an AI platform that gives selected biotech companies access to models trained on data Lilly says cost over USD 1 billion to generate. Federated learning lets partners improve the models without sharing raw data, and Benchling later extended access to its base of more than 1,300 biotech customers.

AI Drug Discovery Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Offering

Services held the largest market share in 2025 because most pharmaceutical companies still buy AI capability as discovery programs instead of stand-alone software. Insilico Medicine, XtalPi, and Recursion sign multi-target collaborations in which they design molecules, run experiments in automated laboratories, and hand over candidates in return for upfront, milestone, and royalty payments. Eli Lilly's March 2026 agreement with Insilico, with USD 115 million upfront and total potential value of about USD 2.75 billion, shows how large sponsors prefer this route for preclinical portfolios. Sponsors gain access to proprietary datasets and robotic laboratories that are costly to build in-house, and they avoid hiring scarce machine learning teams.

Software is projected to grow at the fastest CAGR during the forecast period as research teams place AI tools inside everyday chemistry and biology workflows. Schrödinger added an AI conversational interface to its Maestro modeling environment and released a predictive toxicology beta covering about 50 kinases and key anti-targets in 2025, while Iktos sells its Makya generative design platform as a cloud service. Subscription licences let smaller biotechs start with a few users and scale up, and growing regulatory interest in in silico safety evidence adds further demand for prediction software.

Offering categories include

                    ·           Services (Dominating Segment)

                    ·           Software (Highest CAGR Segment)

Analysis by Technology

Machine learning held the largest market share in 2025 because predictive models for binding, absorption, toxicity, and cell response already sit inside everyday discovery workflows. Numerion Labs applies its AtomNet deep learning models to more than 600 disease targets with over 250 partners, and Schrödinger combines a machine learning force field with physics-based simulation in its molecular design platform. These tools carry years of validation data, connect to existing informatics systems, and give medicinal chemists clear scores to act on, so buyers face little adoption risk. Regulators' growing acceptance of computational evidence for safety assessment gives a further reason to invest in proven predictive models.

Generative AI is projected to grow at the fastest CAGR during the forecast period as models move from scoring existing molecules to creating new ones. Absci's Origin-1 model designs antibodies against new epitopes, and the company reports that it moved its first two programs from AI design into clinical development in about two years at roughly USD 15 million per program, against an industry average of four to six years and more than USD 50 million. Iktos offers Makya as a cloud service and Cradle sells protein design software to pharmaceutical teams. Faster, cheaper candidate creation is pulling more sponsors into generative programs.

Technology categories include

                    ·           Machine Learning (Dominating Segment)

                    ·           Generative AI (Highest CAGR Segment)

                    ·           Natural Language Processing

                    ·           Computer Vision

                    ·           Others

Analysis by Application

Lead optimization held the largest market share in 2025 because this stage has the richest experimental data and the clearest payoff. Medicinal chemists must balance potency, selectivity, safety, and drug-like properties together, and AI models can rank thousands of proposed changes faster than manual design cycles. Iambic's Enchant model predicts clinical properties such as pharmacokinetics from early data, and Schrödinger's free energy calculations estimate binding strength before synthesis. Aqemia's physics-based generative platform covers the path from first hits to development candidate selection for its partners, which shows how vendors package optimization as a paid service.

Target identification is projected to grow at the fastest CAGR during the forecast period because choosing the right target remains the riskiest decision in any program. Owkin's K Pro agent analyzes multimodal patient data to guide target selection in oncology and immunology, Insilico's PandaOmics ranks targets by confidence, tractability, druggability, and mechanism clarity, and insitro uses statistical genetics and machine learning to find targets in neuroscience and metabolism. As more sponsors license both data and AI agents, spending on early target work is expected to rise faster than at later stages.

Application categories include

                    ·           Lead Optimization (Dominating Segment)

                    ·           Target Identification (Highest CAGR Segment)

                    ·           Hit Identification

                    ·           Preclinical Testing

                    ·           Drug Repurposing

Analysis by Therapeutic Area

Oncology held the largest market share in 2025 because cancer programs offer well-defined targets, biomarker-driven trials, and steady sponsor spending. Recursion's clinical pipeline centers on precision oncology assets such as the CDK7 inhibitor REC-617 and the RBM39 degrader REC-1245, while Insilico's TEAD inhibitor ISM6331 and MAT2A inhibitor ISM3412 have entered global Phase I studies. Owkin also licenses its K Pro AI scientist and patient data to sponsors for oncology research, which shows how AI vendors are building repeatable commercial offerings around cancer biology. Crowded competition in targeted therapies also pushes sponsors to seek differentiated molecules faster, which raises demand for design and optimization tools.

Neurology is projected to grow at the fastest CAGR during the forecast period as AI offers a new route into diseases where conventional programs fail often. Recursion's neuroscience collaboration with Roche and Genentech saw Genentech move the first neuroscience target into early discovery in the second quarter of 2026. Insilico expanded its central nervous system collaboration with Tenacia Biotechnology in March 2026, and its NLRP3 candidate ISM8969 received FDA clearance to start a Parkinson's disease trial in January 2026. Limited treatment options and high trial failure rates give sponsors a strong reason to test AI-derived targets and brain-penetrant molecules.

Therapeutic Area categories include

                    ·           Oncology (Dominating Segment)

                    ·           Neurology (Highest CAGR Segment)

                    ·           Infectious Diseases

                    ·           Immunology

                    ·           Metabolic Disorders

                    ·           Others

Analysis by End User

Pharmaceutical companies held the largest market share in 2025 because they own the target portfolios, clinical development capacity, and budgets needed to fund multi-year AI programs. Isomorphic Labs lists Novartis, Eli Lilly, and Johnson & Johnson among its partners, and Owkin licensed its K Pro AI scientist to AstraZeneca, Boehringer Ingelheim, and Servier during 2026. Large sponsors also use several vendors at once across small molecules, antibodies, and patient data analysis, which multiplies the contract value that each sponsor brings to the market. Their existing regulatory teams also make it easier to move AI-designed candidates into clinical development.

Biotechnology companies are projected to grow at the fastest CAGR during the forecast period as AI-native start-ups and small biotechs use software, shared models, and outside capital to compete with larger firms. Absci completed a USD 100 million underwritten offering in 2026 that included a USD 40 million strategic investment from Eli Lilly, and its lead antibody ABS-201 reported positive interim Phase 1 data. Iambic also advances clinical-stage assets designed with AI. As more biotechs move candidates into the clinic, they buy prediction software, custom models, and specialist services at a faster rate than established sponsors.

End User categories include

                    ·           Pharmaceutical Companies (Dominating Segment)

                    ·           Biotechnology Companies (Highest CAGR Segment)

                    ·           Contract Research Organizations

                    ·           Academic and Research Institutes

By Region

AI Drug Discovery Market Regional Analysis

AI Drug Discovery Market Share 2025, (CAGR)

North America

52%

South America

XX%

Europe

22%

Middle East Africa

XX%

Asia Pacific

XX%

Regional Analysis

North America held the largest market share in 2025, accounting for 52% of global market share, because the United States hosts most of the industry's AI-native drug developers, GPU technology providers, and pharmaceutical sponsors. Recursion in Salt Lake City, Absci in Vancouver, Washington, Generate:Biomedicines in Somerville, Iambic in San Diego, and NVIDIA supply platforms and clinical-stage programs, while a deep venture and public equity funding pool lets these companies scale automated laboratories. In Canada, Recursion maintains offices in Toronto and Montréal, which gives the region access to strong machine learning research talent. Sponsors headquartered in the region, including Eli Lilly and AbbVie, are among the most active signers of AI discovery partnerships.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by fast-rising AI drug discovery capacity in China and Japan. In China, XtalPi in Shenzhen combines AI, quantum physics, and robotics, while Insilico Medicine has signed drug discovery collaborations with Hisun Pharma, Qilu Pharmaceutical, and China Medical System, and its lead candidate rentosertib began dosing patients in a Phase III trial at Peking Union Medical College Hospital and Shanghai Pulmonary Hospital in 2026. In Japan, ASKA Pharma partnered with Insilico on target discovery, which shows growing local demand for AI-generated targets. Both countries combine a strong chemistry and manufacturing base with rising pharmaceutical R&D spending, which suits AI-plus-robotics discovery models.

Countries and Regions Covered

Asia-Pacific (Fastest Growing Region)

o  China (Largest Country Market)

o  India (Fastest-Growing Country Market)

o  Japan

o  South Korea

o  Rest of Asia-Pacific

North America (Dominating Region)

o  United States (Largest Country Market)

o  Canada

o  Mexico

Europe

o  Germany

o  France (Fastest-Growing Country Market)

o  United Kingdom (Largest Country Market)

o  Italy

o  Rest of Europe

Latin America

o  Brazil (Largest Country Market)

o  Chile (Fastest-Growing Country Market)

o  Rest of Latin America

Middle East & Africa

o  Saudi Arabia (Largest Country Market)

o  United Arab Emirates (Fastest-Growing Country Market)

o  Rest of Middle East & Africa

Market Share

The AI Drug Discovery Market is fragmented, with no single company holding a dominant share. AI-native drug developers such as Recursion, Insilico Medicine, and Isomorphic Labs compete with software vendors such as Schrödinger, technology providers such as NVIDIA, and model builders such as Chai Discovery and Cradle. Proprietary experimental data, automated laboratories, clinical proof of concept, and access to GPU compute are the main success factors. Leading companies prioritize multi-target agreements with large pharmaceutical sponsors, in-house clinical pipelines, and open model platforms that attract outside developers. Sponsors often work with several AI vendors at once, so companies compete on proof of results instead of exclusivity. Consolidation is visible in Recursion's 2024 combination with Exscientia, and innovation is concentrated in generative antibody design, physics-informed models, agentic AI scientists, and predictive toxicology.

Key Players

                    ·           Recursion Pharmaceuticals (US)

                    ·           Isomorphic Labs (UK)

                    ·           Insilico Medicine (China)

                    ·           XtalPi Holdings (China)

                    ·           Schrödinger, Inc. (US)

                    ·           NVIDIA Corporation (US)

                    ·           Generate Biomedicines, Inc. (US)

                    ·           Chai Discovery (US)

                    ·           Absci Corporation (US)

                    ·           Iambic Therapeutics (US)

                    ·           Numerion Labs (formerly Atomwise) (US)

                    ·           insitro (US)

                    ·           Owkin (France)

                    ·           Iktos (France)

                    ·           Aqemia (France)

                    ·           Cradle (Netherlands)

Recent Market Developments

• In August 2025, XtalPi announced a strategic collaboration with DoveTree Medicines worth up to USD 6 billion, including a USD 51 million upfront payment plus milestone and royalty potential. XtalPi will use its AI, quantum physics, and robotics platform to design candidates for oncology, immunology, neurology, and metabolic targets selected by DoveTree. The agreement shows that Asia-Pacific platform companies can win large multi-target contracts from Western biotech sponsors.
• In December 2025, Insilico Medicine listed on the Main Board of the Hong Kong Stock Exchange on 30 December 2025 under stock code 3696, raising about USD 293 million (HKD 2.277 billion) in the largest Hong Kong biotech IPO of the year. It became the first AI-driven biotech company to list on the Main Board under Chapter 8.05. The listing gives Insilico capital to scale its Pharma.AI platform and clinical pipeline and opens a public-market route for other AI drug developers in the region.
• In February 2026, Generate Biomedicines priced its initial public offering on 26 February 2026 at USD 16 per share, selling 25 million shares for USD 400 million in gross proceeds, and began trading on Nasdaq as GENB the next day. The company designs protein therapeutics with its Generate Platform, and its lead antibody GB-0895 for severe asthma entered a large clinical study in January 2026. The offering was the largest biotechnology IPO of the year at that point.
• May 2026:
• Isomorphic Labs announced a USD 2.1 billion Series B round on 12 May 2026, led by Thrive Capital with Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The funds will scale its IsoDDE drug design engine and move internal programs toward the clinic, with first clinical trials now expected by the end of 2026. The company holds partnerships with Novartis, Eli Lilly, and Johnson & Johnson.
• June 2026:
• Owkin announced on 5 June 2026 a multi-year collaboration with Sanofi to co-develop AI agents for biopharma, backed by a five-year license for its K Pro AI scientist. The agreement builds on a research relationship that began in 2021 and moves Owkin from target identification projects toward agent-based tools embedded in a large sponsor's daily research workflows.
• In September 2026, Iambic and AbbVie announced on 21 September 2026 a multi-year collaboration to apply Iambic's AI platform to small molecule discovery in immunology, neuroscience, and oncology, with programs aimed at first-in-class and best-in-class potential. The agreement shows continued sponsor demand for AI-designed small molecules across three high-value therapeutic areas and gives Iambic a route to test its platform across a broad set of targets chosen with a large pharmaceutical partner.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is AI Drug Discovery?

2

What is the CAGR of the AI Drug Discovery Market?

3

Which offering leads the AI Drug Discovery Market?

4

Which therapeutic area dominates the AI Drug Discovery Market?

5

Which application has the highest market share?

6

What are the latest trends in the AI Drug Discovery Market?

7

Who are the end users of AI Drug Discovery?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates